ADVENTRX Thiovir Preclinical Studies Slated for Presentation at HIV Pathogenesis Conference
January 23 2006 - 10:00AM
PR Newswire (US)
SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that key data from
Thiovir(TM) preclinical studies will be presented at the HIV
Pathogenesis Meeting, in Keystone, Colorado, which takes place
March 27 - April 2, 2006. The abstract entitled "Synergistic
Antiviral Activity and Additive Cytotoxicity of Thiovir Combined
with Zidovudine" is scheduled for presentation on Friday, March 31.
Thiovir is a non-nucleoside reverse transcriptase inhibitor (NNRTI)
designed for oral delivery as a component of AZT-based highly
active antiretroviral therapy (HAART) for HIV/AIDS. "We look
forward to presenting these additional results from our extensive
preclinical synergy studies using Thiovir in conjunction with AZT,"
said Evan M. Levine, ADVENTRX president and CEO. "We believe these
and other recent preclinical studies are convincing evidence in
favor of our clinical strategy for Thiovir in treatment-experienced
HIV/AIDS patients. An investigational new drug application is in
progress and planned to be filed with the FDA during the first half
of 2006." About Thiovir Thiovir is a non-nucleoside reverse
transcriptase inhibitor (NNRTI) designed for oral delivery as a
component of AZT-based highly active antiretroviral therapy
(HAART). Thiovir is a prodrug for foscarnet that delivers both the
active drug TPFA (thiophosphonoformate) and the active metabolite
PFA (foscarnet) in an oral formulation. Thiovir is intended to
deliver the benefits of the drug foscarnet, including broad
spectrum antiviral activity, with the added benefit of improved
cell permeability. ADVENTRX currently plans to file an
investigational new drug application with the US Food and Drug
Administration in the first half of 2006. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. Web site:
http://www.adventrx.com DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, Inc.,
+1-858-552-0866 Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024